Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus

Exclusion Criteria

• •Negative nasal culture for S. aureus on the first screen visit.
• •Negative nasal cultures for S. aureus on second and third screen visits.
• •Concurrent treatment with antimicrobials for an infection.
• •MRSA decolonization attempt in the previous 6 months (prior treatment for a MRSA infection is not an exclusion criterion).
• •Inability to take medications nasally.
• •Nasal surgery in the previous 3 months.
• •Evidence of active rhinitis, sinusitis, or upper respiratory infection.
• •Within the judgment of the Principal Investigator and the Sponsor Medical Monitor, any clinically significant hematologic, endocrine, cardiovascular, hepatic, renal, gastrointestinal, and/or pulmonary disorder; any predisposing condition that might interfere with the absorption, distribution, metabolism, and/or excretion of drugs; or any clinically relevant abnormality identified on physical examination, 12-lead ECG, or clinical laboratories at screening. A single repeat for clinical laboratories or 12- lead ECG will be allowed to determine eligibility.
• •The subject's systolic BP is outside the range of 90-150mmHg, or diastolic BP is outside the range of 45-95mmHg or HR is outside the range of 50-100 bpm for female subjects or 40-100 bpm for male subjects.
• •Subjects who have a history of allergy to the study drug or drugs of this class, or a history of drug or other allergy that, in the opinion of the investigator, contraindicates participation in the trial. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
• •The use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St. John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety. Use of nasal medications is strictly prohibited from 7 days prior to the first screening visit and then 7 days prior to the 2nd screening visit through the final follow-up visit.
• •Treatment with an investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
• •The subject has a history of alcohol or substance abuse or dependence within 12 months of the study: History of regular alcohol consumption averaging \> 7 drinks/wk for women or \> 14 drinks/wk for men. 1 drink is equivalent to 12g alcohol = 5 oz (150ml) of wine or 12oz (360ml) of beer or 1.5 oz (45ml) of 80 proof distilled spirits within six months of screening.
• •Positive for Human Immunodeficiency Virus (HIV) antibody, hepatitis B virus surface antigen or hepatitis C virus antibody at screening.
• •Donation of blood in excess of 500 mL within 56 days prior to dosing. Note: This does not include plasma donation.
• •The subject has a positive urine drug or alcohol screen.
• •The subject has a history of illicit drug abuse or is unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.